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Aim The evidence needed for tropical countries to take informed
decisions on influenza vaccination is scarce. This article reviews
policy, availability, use and effectiveness of seasonal influenza
vaccine in tropical and subtropical countries.
Method Global health databases were searched in three thematic
areas – policy, availability and protective benefits in the context of
human seasonal influenza vaccine in the tropics and subtropics. We
excluded studies on monovalent pandemic influenza vaccine,
vaccine safety, immunogenicity and uptake, and disease burden.
Results Seventy-four countries in the tropics and subtropics
representing 60% of the world’s population did not have a
national vaccination policy against seasonal influenza. Thirty-eight
countries used the Northern Hemisphere and 21 countries the
Southern Hemisphere formulation. Forty-six countries targeted
children and 57 targeted the elderly; though, the age cut-offs varied.
Influenza vaccine supply increased twofold in recent years. However,
coverage remained lower than five per 1000 population. Vaccine
protection against laboratory-confirmed influenza in the tropics
ranged from 0% to 42% in the elderly, 20–77% in children and 50–
59% in healthy adults. Vaccinating pregnant women against
seasonal influenza prevented laboratory-confirmed influenza in both
mothers (50%) and their infants <6 months (49–63%).
Conclusion Guidelines on vaccine composition, priority risk
groups and vaccine availability varied widely. The evidence on
vaccine protection was scarce. Countries in the tropics and
subtropics need to strengthen and expand their evidence-base
required for making informed decisions on influenza vaccine
introduction and expansion, and how much benefit to expect.
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Introduction
Influenza may affect up to 10% of the world’s population
every year 1 with substantial morbidity and mortality.2–5
With immunization being one of the most powerful and cost
effective interventions against infectious diseases,6 vaccina-
tion remains the main strategy to protect populations against
influenza-associated morbidity and mortality. The World
Health Assembly (WHA 56.19) resolved in 2003 to increase
the use of seasonal influenza vaccines to protect individuals
at high risk for influenza and related complications,7 and in
2005, it mandated the WHO (WHA58.5) to work with
international and national partners to increase access to
influenza vaccines.8 The WHO Global Action Plan for
Influenza Vaccines launched in 2006 aims to promote
evidence-based use of seasonal influenza vaccine as a strategy
towards pandemic preparedness.9,10 The immediate goal is to
increase by 2016 the global vaccine production capacity to
produce enough vaccine to equitably immunize 70% of the
world population with a pandemic vaccine that gives an
adequate protection within 6 months of vaccine seed transfer
to manufacturers in the event of a pandemic.11
Over the last decade, an increasing number of countries in
the tropics and subtropics have introduced seasonal
influenza vaccination in their national immunization policies
and/or expanded their policies to include maternal influenza
immunization.12,13 This is critical given the WHO Strategic
Advisory Committee of Experts on Immunization recom-
mendation in 2012 that countries with seasonal influenza
vaccine programmes prioritize persons at high risk of severe
DOI:10.1111/irv.12374
www.influenzajournal.com
Review Article
254 ª 2016 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use,
distribution and reproduction in any medium, provided the original work is properly cited.
influenza virus infection, including pregnant women at any
stage of their pregnancy; children aged 6 months to 5 years,
the elderly and individuals with underlying health conditions
such as HIV/AIDS, asthma and chronic heart or lung
diseases.14 Unlike in the temperate regions, influenza
seasonality in the tropics is less distinct with multiple and
less pronounced peaks with often year-round transmis-
sion.15,16 In the absence of clear guidance on which vaccine
formulation to use and when to vaccinate in the tropics and
subtropics, countries often lack evidence to make informed
decisions. As one of the early steps of a larger WHO effort to
improve seasonal influenza vaccine use and pandemic
preparedness in the tropics and subtropics, this article
reviews the current status of (i) national policy and
guidelines, (ii) coverage and use and (iii) efficacy and
effectiveness, of seasonal influenza vaccine in the context of
the tropics and subtropics.
Methods
The Preferred Reporting Items for Systematic Reviews and
Meta-analysis (PRISMA) statement was used to guide the
process and reporting of our review (Appendix A).17The
outcomes of interest were to review the current status of
national policy for seasonal influenza vaccination, national
guidelines for priority population groups and vaccine
composition, vaccine use and effectiveness. Vaccination
coverage was estimated as the number of vaccine doses
distributed expressed per 1000 population. Vaccine effec-
tiveness estimates were reviewed separately for laboratory-
confirmed influenza, for different risk groups, further
stratified by type of vaccine and antigenic match wherever
possible.
We searched multiple databases (United States National
Library of Medicine, Cochrane Library, WHO Library
Information System, Latin American and Caribbean Health
Sciences Literature, National Databases of Indian Medical
Journals) using different combinations of search terms (with
synonyms and closely related words) such as ‘seasonal
influenza’, ‘influenza vaccine’, ‘tropics’, ‘effectiveness’, ‘effi-
cacy’, ‘policy’, ‘guidelines’, ‘timing’, ‘composition’, ‘cover-
age’, ‘availability’, ‘uptake’, ‘production’, ‘manufacturing’
and ‘campaign’. An example of a search query is shown in
Appendix B. We screened the title and abstract of all articles
to determine eligibility. We also screened other articles that
showed up as related during the search. We retrieved the full
text of all eligible articles and further assessed for inclusion.
We screened articles that were newly identified in the
references cited in the full-text articles. We reviewed all the
past systematic reviews and meta-analyses on vaccine efficacy
and effectiveness as well as all the individual studies that had
been included in these reviews. Duplicates were removed and
the title and abstract were screened for eligibility by two
reviewers independently. Articles were included based on
consensus between the two reviewers. For multiple articles
referring to the same study, we included the article with the
most recent findings. To access grey literature, we first
contacted institutions, networks and individuals known to be
involved in influenza research, used snow-balling technique
to further identify other influenza researchers and searched
conference proceedings and agency reports to identify
ongoing or unpublished studies. Researchers were requested
to share preliminary summaries of unpublished studies to
assess their eligibility for inclusion in the review. We plotted
funnel plots of estimates of vaccine effectiveness and efficacy
for published and unpublished studies separately for elderly,
children and healthy adults to assess the extent of publication
bias if any. We also reviewed four global databases on
seasonal influenza vaccine use administered by the WHO and
UNICEF or maintained by vaccine manufacturers. We
triangulated information regarding influenza policy, guide-
lines and coverage from the different global databases – in
case of discordant findings, we considered the information
from the most recent database as valid.
We limited our review to 138 countries and territories
(excluding Australia) representing 79% of the world’s
population, situated partly or wholly between the north
and south 38th lateral (Appendix C) and restricted our
inclusions to articles in the English language or any other
language provided an abstract was available in English. We
included articles related to policies and guidelines for
seasonal human influenza vaccine use in tropical and
subtropical countries, articles that referred to seasonal
influenza vaccine composition, timing of vaccination, vac-
cine production, availability and coverage, and vaccine
efficacy and effectiveness. We excluded studies that focused
on avian or pandemic influenza vaccine or pandemic
preparedness. Studies on safety and immunogenicity of
influenza vaccines, determinants of influenza vaccine uptake,
licensing and regulatory aspects of influenza vaccine were
also excluded. Studies that focused solely on influenza
seasonality, disease burden, antigenic and genetic character-
istics were beyond the scope of this review. Data was
extracted directly from the full-text articles into structured
tables containing all the relevant variables of interest such as
the status of influenza vaccination policy, year in which
vaccine policy was introduced, vaccine formulation used,
targeted high-risk population groups, whether available in
the private or public sector, vaccine coverage, etc. For vaccine
effectiveness and efficacy studies, we extracted information
on the study year, study design, study population (size and
risk group types), vaccine type (live attenuated or inactive),
formulation used (Northern or Southern Hemisphere),
ascertainment of exposure (i.e. vaccination), outcome (e.g.
influenza-like illness, pneumonia, hospitalization, labora-
tory-confirmed influenza), efficacy, effectiveness and other
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potential confounding factors such as antigenic match of
vaccine with circulating influenza virus. Simple proportions
with 95% confidence intervals, the range of proportions
across different studies, stratified by relevant variables such as
age were used to describe the outcome variables. We did not
repeat a meta-analysis for vaccine efficacy and vaccine
effectiveness, as more than 20 such efforts (including 11
Cochrane Collaboration reviews) have been carried out in
the past. Moreover, we did not identify any new published
studies from the tropics and subtropics since the last meta-
analysis of studies from low- and middle-income countries.18
The risk of bias in the selection and ascertainment of
exposure and outcome for cohort and case–control vaccine
effectiveness studies was assessed independently by two
reviewers (SH and JS) using the Newcastle–Ottawa bias
assessment scale.19 We similarly assessed the methodological
quality for the vaccine efficacy trials based on randomization,
allocation, blinding and follow-up using the Cochrane risk of
bias assessment tool.20 Wherever appropriate, we triangu-
lated information from the global databases to validate the
information extracted from the literature.
Results
Of the 3637 articles and 34 unpublished papers identified as
of 30 September 2014, 3247 were deemed ineligible based on
the screening of the title and abstract. A further 178 articles
were excluded after a full-text appraisal. A total of 215
published (vaccine policy and guidelines – 27, timing and
composition – 49, supply, availability and coverage – 37 and
vaccine efficacy – 102) and 31 unpublished articles (vaccine
policy and guidelines – 8, timing and composition – 4,
supply, availability and coverage – 8 and vaccine efficacy –
11) and four global databases on seasonal influenza vaccine
use were included in the final review (Figure 1). The risk of
bias in selection of the vaccinated cohort, comparability of
the vaccinated and non-vaccinated participants, outcome
ascertainment or differential loss to follow-up was high in
most cohort studies (Appendix D). The risk of bias in
selection of cases or dissimilar non-response rate in cases and
controls was high in most case–control studies
(Appendix E). The risk of bias was lower (except in three
non-randomized controlled trials) in the vaccine efficacy
trials (Appendix F). Most of the published systematic reviews
and meta-analysis (especially the reviews published after
2000) referred to the Cochrane Manual for systematic
reviews; though, only one review explicitly stated that it
adhered to the PRISMA statement. There was no evidence to
suggest publication bias in the context of vaccine effective-
ness studies (results not shown). The review covers 138
countries and territories representing about 79% of the
world’s population situated in the tropics and subtropics.
Seasonal influenza immunization policy
Sixty-four of 138 tropical and subtropical countries repre-
senting 20% of the world’s population had a national
vaccination policy against seasonal influenza (Figure 2).21
Countries such as Bangladesh, China, India, Pakistan and Sri
Lanka in Asia representing about 45% of the world’s
population did not have a national vaccination policy against
influenza. All of Central and South America except Guyana,
Haiti, Saint Kitts & Nevis and Saint Vincent and the
Grenadines had a seasonal influenza immunization policy.22
On the other hand, only six countries (Co^te d’Ivoire, Egypt,
Multiple database search:
No. of published papers identified
(3637)
Search from additionalsources:
No.of unpublished papers identified (34)
No.of global data sets identified (4)
No.of papers excluded (3247) for
reasons of
No.of papers excluded (178) for reasons 
of
Pandemic influenza vaccine studies
Avian influenza virus vaccine studies
Safety, immunogenicity studies
Studies in non-tropical regions (153)
Studies of influenza vaccine for
travellers (5)
Studies of knowledge attitiude
practice, determinants, compliance,
uptake, study with subsequent
update (20)
-
-
-
-
-
-
No. of papers screened based on title
and abstract (3671)
No. of full-text articles assessed for
eligibility (424)
Included in review:
No.of published papers (215)
No.of unpublished papers (31)
No.of global data sets (4)
Figure 1. PRISMA flowchart of selection and exclusion of articles.
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Libya, Mauritius, Tunisia and South Africa) in Africa had a
national immunization policy or guideline against seasonal
influenza.
National policy guidance on vaccine composition was
available for 63 countries – 38 and 21 countries recom-
mended the use of the Northern and Southern Hemisphere
formulation respectively, whereas three countries (Brunei
Darussalam, Marshall Islands and Singapore) recommended
both formulations. Peru experimented with both formula-
tions in 2012 but subsequently reverted to one formulation.
Five countries situated in the Southern Hemisphere tropics
used the Northern Hemisphere formulation, whereas eight
situated in the Northern Hemisphere tropics used the
Southern Hemisphere formulation. Moreover, four countries
(Costa Rica, El Salvador, Guatemala and the Philippines)
situated in the Northern Hemisphere tropics had switched
from a Northern to a Southern Hemisphere formulation in
recent years (Figure 3).
Countries with a national policy for influenza vaccine
followed the WHO recommendations for targeting one or
more high-risk groups – the elderly, children, individuals
with underlying health conditions such as HIV/AIDS, asthma
and chronic heart or lung diseases and healthcare profes-
sionals.14 The age range of children and the elderly targeted
for influenza immunization varied among the countries.23
Forty-six countries targeted children of 6 months to 5 years,
whereas 57 countries targeted the elderly either above 60 or
65 years of age.21 Sixty-one countries targeted individuals
with underlying health conditions such as HIV/AIDS, asthma
and chronic heart or lung diseases. Forty-seven countries
(including 27 in Central and South America) recommended
seasonal influenza immunization during pregnancy. Fifty-
one countries recommended vaccination of healthcare pro-
fessionals against influenza. There was no correlation
between the development status of the country and free
influenza vaccination to healthcare professionals.24,25 A
survey in 2009 showed that 32 of the 35 countries in Central
and South America administered influenza vaccines to their
healthcare professionals through the public health systems.26
Healthcare professionals were more commonly targeted for
vaccination after the 2009 pandemic.25 In Saudi Arabia, the
vaccine was mandatory for all health professionals working
in the Hajj pilgrimage centres of Mecca and Medina. Saudi
Arabia also required all incoming Hajj pilgrims to be
vaccinated against influenza.27,28
Vaccine supply, availability and coverage
Vaccine coverage varied widely across countries
(Appendix G). Seasonal influenza vaccine supply increased
from 350 million doses in 2006 to around 900 million in
2009.29 It increased by 87% between 2004 and 2011 but by
only 3% per annum in the last 3 years.30 Less than 20% of
the global seasonal influenza vaccine was produced by
regional manufacturers in tropical and subtropical coun-
tries.31 In China, despite an 18% annual increase in vaccine
supply since 2005, local manufacturers supplied 325 million
Subtropics
Subtropics
No
Yes
Data not available
Not applicable
Tropics
Tropics
National influenza vaccine policy
Figure 2. Countries in the tropics and subtropics with a national influenza immunization policy.
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doses of seasonal influenza vaccine in 2008–2009 season
against an estimated domestic need of 570 million doses per
year.32 Fourteen manufacturers from the tropical and
subtropical regions received technology transfer support that
was expected to enhance the supply to 795 million doses by
2016.33–36 Vaccine manufacturers in India, Indonesia and
Thailand had since started production of seasonal influenza
vaccine. Mexico, South Africa, Egypt, the Islamic Republic of
Iran, Thailand and Viet Nam were expected to begin
production within 5–10 years.37 There was no production
capacity in sub-Saharan Africa except one facility in South
Africa that filled and packaged imported vaccine.38
Influenza vaccine was available through the public sector
in 50 countries. In another 28 countries, it was available
solely through the private sector. However, usage was low
when the vaccine was available only in the private sector.30
Influenza vaccine was available in 14 of the 31 countries
surveyed in Africa – six through the private sector (Demo-
cratic Republic of the Congo, Senegal, Togo, Uganda,
Zambia and Zimbabwe) and the remaining eight through
both public and private sectors (Cameroon, Co^te d’Ivoire,
Egypt, Kenya, Madagascar, Mauritius, Morocco and South
Africa).39
Despite a twofold increase in recent years, influenza
vaccine coverage was <5 per 1000 general population in
tropical and subtropical countries (Figure 4).40 The greatest
increase in coverage (2008–2011) was seen in Asia. However,
the total number of seasonal influenza vaccine doses
distributed was relatively small at 82 million in 2011.
Coverage, estimated as the proportion of seasonal influenza
vaccine doses distributed in the general population, was <1%
in 2011 in all of Africa (except Algeria, Mauritius, Morocco,
Namibia, Tunisia and South Africa) 39 and Asia (Bangladesh,
India, Indonesia, Myanmar, Nepal and Sri Lanka). The
coverage was 7–12 per 1000 in Singapore despite influenza
vaccines being offered at a cost in public hospitals.41 In
contrast, countries in Central and South America (except
Guatemala, Guyana, Haiti and Jamaica), Mauritius and
China, Hong Kong SAR reported a coverage of more than
one dose per 1000 population.30 Seasonal influenza vaccina-
tion coverage varied widely across different targeted popu-
lation groups (Table 1) in the tropics.
Vaccine efficacy and effectiveness
Vaccine efficacy and effectiveness against different outcomes
such as laboratory-confirmed disease, influenza-like illness,
hospitalization and mortality associated with seasonal
influenza varied widely in different high-risk groups in
tropical and subtropical countries (Appendix H–L). The 21
studies in the elderly that were reviewed comprised four
randomized and two non-randomized controlled trials, seven
cohort studies, four case–controls and four ecological
Subtropics
Subtropics
Tropics
Tropics
Influenza Vaccine Formulation
NH
NH --> SH
NH and SH
SH
Data not available
Not applicable
Figure 3. National guidelines on seasonal influenza vaccine formulation for countries in the tropics and subtropics. NH, Northern Hemisphere; SH,
Southern Hemisphere.
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studies. Seasonal influenza vaccination provided 43–58%
protection in the elderly.18,42,43 The seven studies in healthy
adults comprised one randomized controlled trial, and three
cohorts and case–control studies each. Seasonal influenza
vaccination provided 50–59% protection in healthy
adults.18,44–46 The 12 studies in children comprised nine
randomized controlled trials, one cohort and two case–
control studies. Seasonal influenza vaccination provided 20–
77% in children depending on antigenic match, against
laboratory-confirmed influenza (Table 2).18,47–55 Vaccinating
Subtropics
Subtropics
Tropics
Tropics
<10
10- <50
50- <100
100- <500
Data not available
Not applicable
Seasonal influenza vaccine does /1000 pop.
Figure 4. Seasonal influenza vaccine doses distributed in the tropics and subtropics (2011) (Source: adapted from Ref. 32).
Table 1. Range of estimates for seasonal influenza vaccine coverage in the tropics and subtropics
Seasonal influenza
vaccine coverage Period Countries References
Children 2014 Argentina, Belize, Chile, Colombia, Ecuador, El Salvador,
Mexico, Nicaragua, Panama: >80%; Bolivia
(Plurinational State of), Honduras, Paraguay, Peru, Uruguay: 23–45%
76
2006 Public funded (Chile, China – Province of Taiwan): 23–62%,
User paid (Argentina): 8–10%
77
2011–2012 China – Province of Taiwan: 32–72% 78
2010–2012 Thailand: <2% 79
Elderly 1993–1997
2004–2008
2014
Chile, Costa Rica, Dominican Republic, El Salvador,
Honduras, Mexico and Nicaragua: >75%; Argentina,
Belize, Bolivia (Plurinational State of), Colombia,
Ecuador, Panama, Paraguay, Peru and Uruguay: 20–69%
26,76,80
2000–2003 Brazil: 66–90% 81–91
2006 Public funded (Argentina, Chile, Republic of Korea):
14–41%; User paid (China, South Africa): <10%
77
Pregnant
women
2005–2006
2010–2013
India, China, Hong Kong SAR, Thailand: 0–4% 79,92–94
Healthcare
professionals
2001–2005
2012
Brazil, China, 20–56% 95–97
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Table 2. Range of VE estimates from meta-analytic reviews and individual studies from the tropics and subtropics
Outcome
Range of pooled VE
estimates from
meta-analytic reviews References
Range of VE point
estimates from individual
studies from the tropics
and subtropics References
Elderly
ILI 4–59% 18,61,62 0–76% 42,90,98–101
LCI 43–58% 18,61,62 0–42% 42,43
Pneumonia 30–53% 61,102,103 43% 104
Hospitalization
Influenza-related No effect – 33% 18,62,102,103,105–107 31–77%* 43,80,104,108–117
All-cause 50% –
Mortality
Influenza-related 8–30% 61,62,102,103,106,107 20–53%* 43,104,108,113,
116,118–121All-cause 36–68% No effect – 44%
Children
ILI 31–45%
LAIV: 36%
TIV: 27%
18,63,67,70–72 8–85% 47,101
LCI
Overall 67–74% 18,63–73 20–77% 47–55,114,122,123
LAIV 62–83% 64–72%
TIV 48–72% 33–62%
LAIV good match 61–88% 70–78%
TIV good match 48–81%
LAIV poor match 60–87%
TIV poor match 49–56%
One dose 58% 58%
Two doses 75% 74%**
Influenza A 31–91% 25–57%
Influenza B 45% 0–50%
Healthy adults
ILI
LAIV 10% 18,65,74,124 – 101,125–127
TIV 20–69% 39–73%
LCI
TIV good match 57–80% 18,64–66,74,124 44–46
TIV poor match 44–52%
TIV any match 59–82% 50–59%
TIV influenza A 64% H1N1pdm – 84%,
H3N2 – 33%
TIV influenza B 52% 84%
Pregnant women
ILI in mother
Healthy mothers 0–44% 128–133 0–36% 57,58
HIV-infected mothers – No effect
LCI in mother
Healthy mothers – 50% 58
HIV-infected mothers – 58%
ILI in infant
Healthy mothers No effect 128–133 0–29% 57,58
HIV-infected mothers – No effect
LCI in infant
Healthy mothers – 49–63% 57,58
HIV-infected mothers – 27% (ns)
Preterm/IUGR (infant) 0–72% 134 28–37% (ns) 57
High-risk individuals
COPD patients
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school children provided 233% (663–749) protection
against influenza and indirect protection of 61% (58–847)
for household contacts.56 Vaccinating pregnant women
prevented laboratory-confirmed influenza in both mothers
(50%) and their infants up to 6 months of age (49–63%).57,58
Vaccinating patients with chronic obstructive pulmonary
disease provided 70% protection against laboratory-con-
firmed influenza in Thailand.59
Discussion
This paper presents a comprehensive review of influenza
policy, availability, coverage, use and effectiveness of seasonal
influenza vaccine currently in the tropics and subtropics.
Most countries in Europe, United States and the developed
world have a national policy on immunization against
seasonal influenza.21,60 In contrast, large parts of sub-Saharan
Africa and the Indian subcontinent are yet to formulate
national policies against seasonal influenza; though, the
vaccine is available through the private sector in many
countries in the region. Historically, the Central and South
Americas have often led the introduction of new and
underused vaccines including expansion of seasonal influ-
enza vaccine to pregnant women. Even as some countries
such as the United States expand their policy to immunize all
individuals above 6 months of age against influenza, targeted
vaccination of high-risk population subgroups remains the
main strategy to reduce influenza disease burden. Many
countries in the tropics recommended the Northern or
Southern Hemisphere vaccine formulation based on geo-
graphical location rather than on evidence on local season-
ality and antigenic evolution patterns.
Overall, seasonal influenza vaccination coverage was <1%
in most parts of Africa and Asia. In contrast, reported
coverage in the Central and South America was comparable
to that seen in high-income countries.30 Higher vaccination
coverage is not correlated with higher level of economic
development. Higher coverage, however, is seen when the
vaccine is offered at no cost through the public sector.12
Estimating influenza vaccine coverage poses major challenges
for countries in the tropics and subtropics – lack of special
vaccine coverage studies, suboptimal definition of coverage,
absence of reliable denominators for the targeted high-risk
population groups, lack of information on unused or
returned or wasted vaccine doses, among others. Vaccine
coverage estimated by national immunization programmes is
less meaningful as they are based on the number of vaccine
doses distributed or administered expressed as a fraction of
number of doses procured. Global distribution of vaccines by
the major manufacturers has been used as a proxy for vaccine
coverage.30 However, these coverage estimates do not
account for 21% of the global vaccine supply by developing
country manufacturers that do not contribute to this
database.
Table 2. (Continued)
Outcome
Range of pooled VE
estimates from
meta-analytic reviews References
Range of VE point
estimates from individual
studies from the tropics
and subtropics References
ARI 11% (ns) 135 60–85% 59,136,137
LCI 81% 71%
Hospitalization (ARI) 67% (ns) 72%
Coronary heart disease patients
Coronary heart disease mortality 61% 138 38 (ns) – 66% 139,140
HIV-infected patients
ARI – 141,142 8 (ns) – 16% (ns) 143
LCI 27–78% 76%
Healthcare professionals No effect on LCI,
hospitalization
or mortality in elderly
who received care
from healthcare professionals
144 51% against ILI in health
workers if good antigenic
match; no effect if poor
antigenic match
145
Pilgrims
ILI 72% 18 38–77% 146,147
ARI, acute respiratory illness; COPD, chronic obstructive pulmonary disease; HIV, human immunodeficiency virus; ILI, influenza-like illness; LAIV, live
attenuated influenza vaccine; LCI, laboratory-confirmed influenza; TIV, trivalent inactivated influenza vaccine; VE, vaccine efficacy and effectiveness.
*No effect in two studies.
**One study showed protective effect only after two doses.
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Our review suggests that the 43–58% protection by the
vaccine against laboratory-confirmed influenza in the elderly
was slightly lower in the tropics and subtropics compared to
50–77% protection seen in Europe, United States and other
developed countries.61,62 The protection in children (range
20–77%) and in healthy adults (range 50–59%) seen in the
tropics and subtropics was comparable with that seen in
developed countries.63–74 Vaccine protection studies from
the tropics and subtropics faced certain limitations. First,
the majority of the studies from the tropics and subtropics
were observational and prone to selection or ascertainment
bias. The outcome for assessing vaccine protection was
based on clinical ascertainment or self-reports without
laboratory confirmation of influenza. Three of 16 vaccine
efficacy trials were non-randomized and prone to ascertain-
ment and reporting bias. Second, most studies were from
large urban areas with limited national representativeness.
Third, few studies matched for antigenic relatedness of the
circulating influenza virus with the vaccine virus strain.
Vaccine effectiveness is known to be low during seasons of
antigenic mismatch as was seen during the 2014–2015
influenza season in the United States when protection was
much lower [18% (95% CI: 6–29%)] against A(H3N2)
viruses.75
Notwithstanding these challenges, vaccine effectiveness
data is critical for countries to introduce and evaluate
influenza vaccination programmes. Even as an increasing
number of countries from the tropics and subtropics
introduce influenza into their immunization programme,
there are critical knowledge gaps in these settings. It is not
known how the high prevalence of underlying malnutrition
and infections such as tuberculosis, malaria and limited
access to health care may increase the risk of influenza-
related complications or may influence vaccine effectiveness.
Although children and the elderly are at high risk of severe
influenza outcomes, few studies from the tropics and
subtropics assessed severe outcomes such as influenza-related
hospitalization or mortality. Almost a third of these studies
were observational and prone to bias due to self-assessment
of the influenza outcomes. Only a few studies evaluated
vaccine effectiveness stratified by antigenic match or reported
data on vaccine coverage, influenza incidence and seasonal-
ity.64 Finally, waning immunity in the months following
vaccination may decrease vaccine benefits in tropical and
subtropical regions where influenza activity prevails all year
round. Countries need to strengthen their national surveil-
lance for influenza that integrate methodologies to measure
vaccine coverage and evaluate vaccine effectiveness using
well-defined denominators.
Our review, though systematic, was subject to several
methodological and substantive limitations. First, we
excluded articles in languages other than English. However,
we took efforts to search regional databases for articles in
Spanish language as countries from Central and South
America have contributed substantially to influenza research
in the recent past. An earlier review of influenza (seasonal
and pandemic) vaccine effectiveness in low- and middle-
income countries identified 132 articles of a total of 361, in
languages other than English.18 More than 75% of these non-
English language articles were from Russia and another 15
articles were from Romania, countries that were outside the
scope of our review. Nevertheless, our review may be limited
to some extent by the exclusion of potential studies from
China.
Second, there was wide disparity in the geographic
distribution of studies. For example, of the 26 studies from
the tropics and subtropics of vaccine effectiveness among
the elderly, 11 (including nine from Brazil,) were from
Central and South America, 12 from Asia Pacific (including
four each from China and Hong Kong SAR, three from
Thailand and two from China – Province of Taiwan), and
three from Africa (all from South Africa). Most of sub-
Saharan Africa, the Middle East, Bangladesh, India, Indone-
sia, Pakistan and Sri Lanka in Asia were underrepresented in
the review.
Conclusion
Seventy-four countries in the tropics and subtropics repre-
senting 60% of the world’s population did not have a
national vaccination policy against seasonal influenza.
Guidelines on vaccine composition, priority risk groups
and vaccine availability in the public and private sector
varied widely. Influenza vaccination coverage was <5 per
1000 general population. The evidence on vaccine effective-
ness in the tropics and subtropics was scarce. Countries in
the tropics and subtropics need to strengthen and expand
their local and regional evidence-base required for making
informed decisions on influenza vaccine introduction and
expansion, and how much benefit to expect.
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